Peregrine Pharmaceuticals, Inc. (NASDAQ-PPHM) is a biopharmaceutical company developing and manufacturing innovative monoclonal antibodies for the treatment of cancer and serious viral infections.
Interview with Thorpe July 2009
The Behavioral Medicine Report
An Interview With Philip Thorpe, Lead Researcher Of The Recent Bavituximab Study
bmedreport.com
Author's Resume'
bmedreport.com
Upcoming conferences
Chemical and Biological Defense Science and Technology (CBD S&T) Conference
Dallas, Texas, 16-20 November 2009
T028 Phosphatidylserine-Targeting Antibodies as Therapeutic Agents for Viral Hemorrhagic Fever Infections
Amy Brideau-Andersen, Peregrine Pharmaceuticals; Melina Soares, University of Texas Southwestern Medical Center; Philip Thorpe, University of Texas Southwestern Medical Center; Brian Gowen, University of Utah; Justin Julander, University of Utah; Ashley Grant, University of Texas Medical Branch; Clarence Peters, University of Texas Medical Branch; Mary Wakabayashi, Peregrine Pharmaceuticals; Kyle Schlunegger, Peregrine Pharmaceuticals; Bruce Freimark, Peregrine Pharmaceuticals;
cbdstconf.sainc.com
Antibody Biology & Engineering
From Basic Mechanisms To Antibody-Based Therapeutics
March 7-12, 2010
Ventura Beach Marriott
Ventura, CA
• Therapeutic Antibodies
(Andrew Chan / Philip Thorpe / Wayne Marasco / Steve Jacobsen)
grc.org
A new national initiative involving where volunteers can be matched to a scientific research project, or clinical trial, for which they might qualify.
Interested adult volunteers, parents or caregivers register on the ResearchMatch Web site (www.researchmatch.org) and indicate their interest in participating in research studies. Both healthy volunteers and those with specific medical conditions can sign up.
Message 26090452 |
